ArticleJournal of clinical laboratory analysis2020
Identification of potential metabolite markers for colon cancer and rectal cancer using serum metabolomics.
Article in Journal of clinical laboratory analysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Colorectal neoplasia-specific amino acid profiles and their diagnostic potential: a systematic review.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Pooled it
- Metabolic Signatures: Pioneering the Frontier of Rectal Cancer Diagnosis and Response to Neoadjuvant Treatment with Biomarkers-A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Potential Impact of Microbial Dysbiosis and Tryptophan Metabolites in Advanced Stages of Colorectal Cancer.Biomedicines · 2025Article
- Metabolic and proteomic signatures differentiate inflammatory phenotypes from cancer and predict treatment response in patient sera.Bioengineering & translational medicine · 2025Article
- Genetic determinants of head and neck cancer: exploring causality among immune cells and plasma metabolites through two-sample Mendelian randomization and mediation analysis.Discover oncology · 2025Article
- Altered metabolic profiles in colon and rectal cancer.Scientific reports · 2025Article
- Multi-omics machine learning to study host-microbiome interactions in early-onset colorectal cancer.NPJ precision oncology · 2024Article
- Plasma metabolomic differences in early-onset compared to average-onset colorectal cancer.Scientific reports · 2024Article
- Review
- Untargeted plasma metabolomics and risk of colorectal cancer-an analysis nested within a large-scale prospective cohort.Cancer & metabolism · 2023Article
- Comprehensive Insight into Colorectal Cancer Metabolites and Lipids for Human Serum: A Proof-of-Concept Study.International journal of molecular sciences · 2023Article
- Signaling pathways in cancer metabolism: mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2023Review
- Systematic Review: Contribution of the Gut Microbiome to the Volatile Metabolic Fingerprint of Colorectal Neoplasia.Metabolites · 2022Review
- Association of levels of metabolites with the safe margin of rectal cancer surgery: a metabolomics study.BMC cancer · 2022Article
- Integrated microbiome, metabolome, and proteome analysis identifies a novel interplay among commensal bacteria, metabolites and candidate targets in non-small cell lung cancer.Clinical and translational medicine · 2022Article
- The Application of Metabolomics in Recent Colorectal Cancer Studies: A State-of-the-Art Review.Cancers · 2022Review
- Serum Colorectal Cancer Biomarkers Unraveled by NMR Metabolomics: Past, Present, and Future.Analytical chemistry · 2022Article
- Review
- Predictive Value of Red Blood Cell Distribution Width in Poststroke Depression.Computational and mathematical methods in medicine · 2021Observational
- Identification of potential metabolite markers for colon cancer and rectal cancer using serum metabolomics.Journal of clinical laboratory analysis · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundTo determine the metabolic characteristics of patients with colon cancer (CC) and rectal cancer (RC) using gas chromatography-mass spectrometry (GC-MS)-based metabolomics.
methodsIn this study, serum samples were collected from 22 CC patients and 23 RC patients preoperatively and postoperatively and 45 healthy volunteers (HVs), and subjected to metabolomics analysis by GC-MS. Differential metabolites in the preoperative RC and CC samples and HVs were identified as potential biomarkers and evaluated for their utilities by receiver operating characteristic analyses.
resultsThe different metabolic markers between CC and RC patients were identified, which may assist in distinguishing the two types of cancers. The area under the curve (AUC) was 0.805 for combination of d-glucose and d-mannose for CC diagnosis, and 0.889 for combination of 2-aminobutanoic acid, 3-hydroxypyridine, d-glucose, d-mannose, isoleucine, l-tryptophan, urea, and uric acid for RC diagnosis. The combinations of metabolite markers showed a better predictability than CEA and CA199 two commonly used protein markers for CRC diagnosis in clinical practice. Combining the metabolite markers with these two protein markers effectively improved the diagnostic accuracy with the AUC reaching 0.936 and 0.937 for CC and RC diagnosis, respectively.
conclusionsMetabolic profiles are different in the blood samples between CC and RC patients. The study has established a panel of metabolic markers as a predictive and multiplexing signature for CC and RC diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.